Biotechnology
出席上海國際腫瘤內科學論壇（第 7 屆 SIMOS）的重點公司 – MEDSIR
腫瘤學獨立臨床研究的領先機構 MEDSIR 加強與國際間合作及科學知識交流的承諾。MEDSIR 高級科學主管 Anton
MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS)
MEDSIR, a leader in independent clinical research in oncolog
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion unveils post-combination technology-enabled portfo
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Numab to receive R&D funding for the preclinical develop
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
SPRING, Texas, Nov. 08, 2024 (GLOBE NEWSWIRE) — Io Therapeu
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
– Improved safety and efficacy profiles for ADG126 versus ip
The world’s first 100% “fiber-to-fiber” biorecycled clothing unveiled by multi-brand consortium: CARBIOS, On, Patagonia, PUMA, PVH Corp. and Salomon
For the first time, a piece of clothing is made entirely fr
Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities
HYDERABAD, India, Oct. 28, 2024 (GLOBE NEWSWIRE) — Sai Life
Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024
SAN FRANCISCO and SINGAPORE, Oct. 23, 2024 (GLOBE NEWSWIRE)
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
REC-3964 is Recursion’s first new chemical entity developed
VedTechBio® Launches RxAgentAI™ – an Artificial Intelligence and Machine Learning Platform, catering to the decision making and strategic needs of stakeholders in the life sciences industry AND VedTechBio® Announces a Drug Discovery Collaboration with RenaissThera®
BENGALURU, India, Oct. 16, 2024 (GLOBE NEWSWIRE) — VedTechB
【時事評論】傾聽真民意 建高效團隊
2024環球選舉年最矚目一戰，美國總統大選結果終於揭盅，前總統特朗普大勝現任副總統賀錦麗，明年一月再入主白宮，出任美國總統。雖然很多關注人士及各國政要都有這一預感，甚至已作好一定準備，但當預感變成事實，相信仍感錯愕。毫無疑問，特朗普再次執政將為美國以至全世界的政治經濟帶來一波大改變，是福是禍？現階段難說得很，因特朗普是個難以預測的政治人物。惟可以肯定的是，任何大變化都會影響澳門，哪怕只間接關係，新屆特區政府有為此作準備嗎？
甄慶悅
【主編前言】又見新規劃
早前政府向城規會介紹新一份《青洲都市化整治計劃》，調整後的總用地面積維持23.8萬平方米，但新計劃提出將青洲山保育面積增大兩倍多，居住人口則由2.7萬人大幅調低至1.3萬人。增加綠化面積，減少居住人口數量，如按新計劃實施，整治後的青洲區居住環境自然會有質的飛躍。
Mandy Kuok